lactic acid has been researched along with Vaginosis, Bacterial in 34 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Vaginosis, Bacterial: Polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli. It remains unclear whether the initial pathogenic event is caused by the growth of anaerobes or a primary decrease in lactobacilli.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Significant reduction of malodorous vaginal discharge (whiff test) and lowest recurrence of BV were noted in the metronidazole plus lactic acid gel arm." | 5.12 | Metronidazole with Lactacyd vaginal gel in bacterial vaginosis. ( Co, JT; Dancel, LA; Decena, DC; Lelis, MA; Manalastas, RM; Padolina, CS; Palaypayon, EP; Sison, JM, 2006) |
| "Lactic acid gel was associated with fewer reported side effects." | 3.30 | Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial. ( Abdali, Z; Anstey Watkins, J; Armstrong-Buisseret, LK; Brittain, C; Daniels, J; David, M; Dean, G; Griffiths, F; Hepburn, TM; Jackson, L; Kai, J; Manley, A; Montgomery, A; Ozolins, M; Ross, JDC, 2023) |
| "Lactic acid gel was less cost-effective than metronidazole." | 3.11 | Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT. ( Abdali, Z; Anstey Watkins, J; Armstrong-Buisseret, L; Brittain, C; Daniels, J; David, M; Dean, G; Griffiths, F; Hepburn, T; Jackson, L; Kai, J; Manley, A; Montgomery, A; Ozolins, M; Ross, JD, 2022) |
| "'Metronidazole Versus lactic acId for Treating bacterial vAginosis' (VITA) is a UK-based randomised controlled trial assessing clinical and cost-effectiveness of topical lactic acid gel compared to oral metronidazole antibiotic for treating second and subsequent BV episodes." | 2.90 | Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial. ( Anstey Watkins, J; Brittain, C; Griffiths, F; Kai, J; Ross, JDC; Thandi, S, 2019) |
| " No adverse events related to the investigational product occurred." | 2.82 | Rationale and Safety Assessment of a Novel Intravaginal Drug-Delivery System with Sustained DL-Lactic Acid Release, Intended for Long-Term Protection of the Vaginal Microbiome. ( Remon, JP; Verstraelen, H; Vervaet, C, 2016) |
| "Lactic acid has properties that may make it effective for treating BV and/or restoring an optimal lactobacillus-dominated vaginal microbiota." | 2.72 | Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review. ( Bateson, D; Bradshaw, CS; Doyle, M; Fairley, CK; Masson, L; Murray, GL; Plummer, EL; Slifirski, J; Tachedjian, G; Vodstrcil, LA, 2021) |
| "To evaluate the effect of treatment of bacterial vaginosis with the product Arilin rapid containing vaginal Metronidazole in high doses and a following vaginal application of lactic acid in a part of the patients." | 2.70 | [Treatment of bacterial vaginosis with high dosage metronidazole and lactic acid]. ( Andreeva, P; Kovachev, S; Nacheva, A; Slavchev, B; Vacheva, R, 2002) |
| "During bacterial vaginosis (BV), populations of lactobacilli which are generally dominant in the vagina of overtly healthy women are replaced by other facultative and anaerobic microorganisms." | 2.40 | Microbial interactions in the vaginal ecosystem, with emphasis on the pathogenesis of bacterial vaginosis. ( Onderdonk, AB; Pybus, V, 1999) |
| "Lactic acid (LA) is a major organic acid metabolite produced by vaginal lactobacilli that elicits anti-inflammatory effects from cervicovaginal epithelial cells and is dramatically depleted during BV." | 1.51 | Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota. ( Delgado-Diaz, DJ; Gugasyan, R; Hayward, JA; Hearps, AC; Tachedjian, G; Tyssen, D, 2019) |
| "Glycogen levels were significantly lower in both rhesus (median=0." | 1.38 | A comparison of lower genital tract glycogen and lactic acid levels in women and macaques: implications for HIV and SIV susceptibility. ( Gilbert, D; Kendrick, SR; Mirmonsef, P; Spear, GT; Veazey, RS; Wang, J, 2012) |
| "Bacterial vaginosis is a common condition associated with increased risk of sexually transmitted diseases, including human immunodeficiency virus infections." | 1.33 | Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. ( Ganz, T; Valore, EV; Wiley, DJ, 2006) |
| "3." | 1.31 | [Application of 2% clindamycin cream in the treatment of bacterial vaginosis and valuation of methylcellulose gel containing the complex of Chitosan F and PVP k-90 with lactic acid as carrier for intravaginally adhbited medicines in the cases of pregnanci ( Heimrath, J; Hirnle, G; Hirnle, L; Kłósek, A; Małolepsza-Jarmołowska, K; Woytoń, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 8 (23.53) | 29.6817 |
| 2010's | 16 (47.06) | 24.3611 |
| 2020's | 7 (20.59) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong-Buisseret, L | 2 |
| Brittain, C | 4 |
| Kai, J | 4 |
| David, M | 3 |
| Anstey Watkins, J | 3 |
| Ozolins, M | 2 |
| Jackson, L | 3 |
| Abdali, Z | 2 |
| Hepburn, T | 2 |
| Griffiths, F | 4 |
| Montgomery, A | 3 |
| Daniels, J | 2 |
| Manley, A | 2 |
| Dean, G | 3 |
| Ross, JD | 1 |
| Kerry-Barnard, S | 1 |
| Zhou, L | 1 |
| Phillips, L | 1 |
| Furegato, M | 1 |
| Witney, AA | 1 |
| Sadiq, ST | 1 |
| Oakeshott, P | 1 |
| Mahmoud, MY | 1 |
| Wesley, M | 1 |
| Kyser, A | 1 |
| Lewis, WG | 1 |
| Lewis, AL | 1 |
| Steinbach-Rankins, JM | 1 |
| Frieboes, HB | 1 |
| Ross, JDC | 3 |
| Hepburn, TM | 1 |
| Armstrong-Buisseret, LK | 1 |
| Thandi, S | 2 |
| Roberts, T | 1 |
| Delgado-Diaz, DJ | 1 |
| Tyssen, D | 1 |
| Hayward, JA | 1 |
| Gugasyan, R | 1 |
| Hearps, AC | 1 |
| Tachedjian, G | 2 |
| Happel, AU | 1 |
| Kullin, B | 1 |
| Gamieldien, H | 1 |
| Wentzel, N | 1 |
| Zauchenberger, CZ | 1 |
| Jaspan, HB | 1 |
| Dabee, S | 1 |
| Barnabas, SL | 1 |
| Jaumdally, SZ | 1 |
| Dietrich, J | 1 |
| Gray, G | 1 |
| Bekker, LG | 1 |
| Froissart, R | 1 |
| Passmore, JS | 1 |
| Nunn, KL | 1 |
| Clair, GC | 1 |
| Adkins, JN | 1 |
| Engbrecht, K | 1 |
| Fillmore, T | 1 |
| Forney, LJ | 1 |
| Plummer, EL | 1 |
| Bradshaw, CS | 1 |
| Doyle, M | 1 |
| Fairley, CK | 1 |
| Murray, GL | 1 |
| Bateson, D | 1 |
| Masson, L | 1 |
| Slifirski, J | 1 |
| Vodstrcil, LA | 1 |
| Verstraete, G | 1 |
| Vandenbussche, L | 1 |
| Kasmi, S | 1 |
| Nuhn, L | 1 |
| Brouckaert, D | 1 |
| Van Renterghem, J | 1 |
| Grymonpré, W | 1 |
| Vanhoorne, V | 1 |
| Coenye, T | 1 |
| De Geest, BG | 1 |
| De Beer, T | 1 |
| Remon, JP | 2 |
| Vervaet, C | 2 |
| Laghi, L | 1 |
| Picone, G | 1 |
| Cruciani, F | 1 |
| Brigidi, P | 1 |
| Calanni, F | 1 |
| Donders, G | 1 |
| Capozzi, F | 1 |
| Vitali, B | 1 |
| Beghini, J | 3 |
| Linhares, IM | 3 |
| Giraldo, PC | 3 |
| Ledger, WJ | 2 |
| Witkin, SS | 4 |
| Nasioudis, D | 1 |
| Bongiovanni, AM | 1 |
| Abdelmaksoud, AA | 1 |
| Koparde, VN | 1 |
| Sheth, NU | 1 |
| Serrano, MG | 1 |
| Glascock, AL | 1 |
| Fettweis, JM | 1 |
| Strauss, JF | 1 |
| Buck, GA | 1 |
| Jefferson, KK | 1 |
| Verstraelen, H | 1 |
| Santos, CMA | 1 |
| Pires, MCV | 1 |
| Leão, TL | 1 |
| Hernández, ZP | 1 |
| Rodriguez, ML | 1 |
| Martins, AKS | 1 |
| Miranda, LS | 1 |
| Martins, FS | 1 |
| Nicoli, JR | 1 |
| Garg, KB | 1 |
| Ganguli, I | 1 |
| Kriplani, A | 1 |
| Lohiya, NK | 1 |
| Thulkar, J | 1 |
| Talwar, GP | 1 |
| Atassi, F | 2 |
| Servin, AL | 2 |
| Malinova, M | 1 |
| Mirmonsef, P | 1 |
| Gilbert, D | 1 |
| Veazey, RS | 1 |
| Wang, J | 1 |
| Kendrick, SR | 1 |
| Spear, GT | 1 |
| O'Hanlon, DE | 1 |
| Moench, TR | 1 |
| Cone, RA | 1 |
| Andreeva, P | 1 |
| Slavchev, B | 1 |
| Kovachev, S | 1 |
| Nacheva, A | 1 |
| Vacheva, R | 1 |
| MERFERT, K | 1 |
| Tansupasiri, A | 1 |
| Puangsricharern, A | 1 |
| Itti-arwachakul, A | 1 |
| Asavapiriyanont, S | 1 |
| Decena, DC | 1 |
| Co, JT | 1 |
| Manalastas, RM | 1 |
| Palaypayon, EP | 1 |
| Padolina, CS | 1 |
| Sison, JM | 1 |
| Dancel, LA | 1 |
| Lelis, MA | 1 |
| Valore, EV | 1 |
| Wiley, DJ | 1 |
| Ganz, T | 1 |
| Brassart, D | 1 |
| Grob, P | 1 |
| Graf, F | 1 |
| Hirnle, L | 2 |
| Małolepsza-Jarmołowska, K | 2 |
| Kubis, AA | 1 |
| Hirnle, P | 1 |
| Donders, GG | 1 |
| Desmyter, J | 1 |
| Vereecken, A | 1 |
| Pybus, V | 1 |
| Onderdonk, AB | 1 |
| Heimrath, J | 1 |
| Woytoń, J | 1 |
| Kłósek, A | 1 |
| Hirnle, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis[NCT02314429] | Phase 1 | 6 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| The Human Microbiome in pPROM, Preterm Birth and the Neonatal Infant: a Prospective Longitudinal Pilot-study[NCT04489056] | 100 participants (Anticipated) | Observational | 2020-07-27 | Recruiting | |||
| Host Response to Pessaries in Microbial Communities of the Postmenopausal[NCT02605135] | 84 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lactic acid and Vaginosis, Bacterial
| Article | Year |
|---|---|
Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review.
Topics: Administration, Intravaginal; Female; Humans; Lactic Acid; Microbiota; Publication Bias; Risk; Vagin | 2021 |
The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth.
Topics: Female; Humans; Hydrogen-Ion Concentration; Lactic Acid; Lactobacillus; Microbiota; Premature Birth; | 2015 |
Microbial interactions in the vaginal ecosystem, with emphasis on the pathogenesis of bacterial vaginosis.
Topics: Antibiosis; Bacterial Physiological Phenomena; Ecosystem; Female; Humans; Hydrogen Peroxide; Hydroge | 1999 |
8 trials available for lactic acid and Vaginosis, Bacterial
| Article | Year |
|---|---|
Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT.
Topics: Adolescent; Cost-Benefit Analysis; Female; Humans; Lactic Acid; Metronidazole; Quality of Life; Tech | 2022 |
Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial.
Topics: Ambulatory Care Facilities; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lactic | 2023 |
Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Bacterial Agents; Female; Gels; Humans; L | 2019 |
Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosi
Topics: Administration, Intravaginal; Anti-Bacterial Agents; Comparative Effectiveness Research; Cost-Benefi | 2019 |
Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis.
Topics: Adolescent; Adult; Bacteroidaceae Infections; Clindamycin; Drug Resistance, Bacterial; Female; Gardn | 2020 |
Rationale and Safety Assessment of a Novel Intravaginal Drug-Delivery System with Sustained DL-Lactic Acid Release, Intended for Long-Term Protection of the Vaginal Microbiome.
Topics: Administration, Intravaginal; Adult; Delayed-Action Preparations; Drug Delivery Systems; Female; Hum | 2016 |
[Treatment of bacterial vaginosis with high dosage metronidazole and lactic acid].
Topics: Administration, Intravaginal; Anti-Infective Agents; Female; Humans; Lactic Acid; Metronidazole; Vag | 2002 |
Metronidazole with Lactacyd vaginal gel in bacterial vaginosis.
Topics: Adult; Anti-Infective Agents; Drug Combinations; Female; Humans; Hydrogen-Ion Concentration; Immune | 2006 |
23 other studies available for lactic acid and Vaginosis, Bacterial
| Article | Year |
|---|---|
Vaginal microbiota in ethnically diverse young women who did or did not develop pelvic inflammatory disease: community-based prospective study.
Topics: Adult; Female; Humans; Lactic Acid; Microbiota; Pelvic Inflammatory Disease; Prospective Studies; RN | 2022 |
Lactobacillus crispatus-loaded electrospun fibers yield viable and metabolically active bacteria that kill Gardnerella in vitro.
Topics: Anti-Bacterial Agents; Bacteria; Female; Gardnerella; Gardnerella vaginalis; Humans; Lactic Acid; La | 2023 |
Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota.
Topics: Anti-Inflammatory Agents; Chemokines; Cytokines; Epithelial Cells; Fatty Acids, Volatile; Female; HI | 2019 |
Amylases in the Human Vagina.
Topics: Adult; alpha-Amylases; Female; Glycogen; Humans; Hydrogen-Ion Concentration; Lactic Acid; Lactobacil | 2020 |
Thermoplastic polyurethane-based intravaginal rings for prophylaxis and treatment of (recurrent) bacterial vaginosis.
Topics: Administration, Intravaginal; Drug Delivery Systems; Drug Liberation; Female; Humans; Lactic Acid; M | 2017 |
Rifaximin modulates the vaginal microbiome and metabolome in women affected by bacterial vaginosis.
Topics: Acetic Acid; Adult; Anti-Bacterial Agents; Female; Gardnerella vaginalis; Humans; Lactic Acid; Lacto | 2014 |
Differential expression of lactic acid isomers, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-8 in vaginal fluid from women with vaginal disorders.
Topics: Adult; Basigin; Body Fluids; Brazil; Candidiasis, Vulvovaginal; Cross-Sectional Studies; Enzyme-Link | 2015 |
Neutrophil Gelatinase-Associated Lipocalin Concentration in Vaginal Fluid: Relation to Bacterial Vaginosis and Vulvovaginal Candidiasis.
Topics: Acute-Phase Proteins; Adult; Biomarkers; Body Fluids; Candidiasis, Vulvovaginal; Case-Control Studie | 2015 |
α-Amylase in Vaginal Fluid: Association With Conditions Favorable to Dominance of Lactobacillus.
Topics: Acute-Phase Proteins; Adult; alpha-Amylases; Candidiasis, Vulvovaginal; Case-Control Studies; Epithe | 2015 |
Comparison of Lactobacillus crispatus isolates from Lactobacillus-dominated vaginal microbiomes with isolates from microbiomes containing bacterial vaginosis-associated bacteria.
Topics: Bacteriophages; DNA, Bacterial; Female; Genetic Variation; Genome, Bacterial; Humans; Lactic Acid; L | 2016 |
Selection of Lactobacillus strains as potential probiotics for vaginitis treatment.
Topics: Anti-Infective Agents; Apoptosis; Bacterial Adhesion; Biofilms; Candida albicans; Candidiasis, Vulvo | 2016 |
Metabolic properties of lactobacilli in women experiencing recurring episodes of bacterial vaginosis with vaginal pH >or= 5.
Topics: Adult; Female; Humans; Hydrogen-Ion Concentration; Lactic Acid; Lactobacillus; Recurrence; Vagina; V | 2010 |
Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosis-associated pathog
Topics: Anti-Bacterial Agents; Antibiosis; Drug Synergism; Enterobacteriaceae; Female; Gardnerella vaginalis | 2010 |
[Lactobor Intim vaginal gel for the treatment and prevention of bacterial vaginosis].
Topics: Anti-Bacterial Agents; Female; Humans; Hydrogen-Ion Concentration; Lactic Acid; Vagina; Vaginal Crea | 2009 |
A comparison of lower genital tract glycogen and lactic acid levels in women and macaques: implications for HIV and SIV susceptibility.
Topics: Animals; Disease Susceptibility; Female; Glycogen; HIV Antibodies; HIV Infections; HIV-1; Humans; La | 2012 |
In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide.
Topics: Adolescent; Adult; Anaerobiosis; Anti-Bacterial Agents; Bacteria; Colony Count, Microbial; Female; H | 2011 |
[Therapy of nonspecific colpitis in medical practice].
Topics: Carbohydrates; Female; Humans; Lactic Acid; Stilbenes; Vaginitis; Vaginosis, Bacterial; Vulvovaginit | 1958 |
Satisfaction and tolerability of combination of lactoserum and lactic acid on the external genitalia in Thai women.
Topics: Adult; Aged; Drug Combinations; Female; Genitalia, Female; Humans; Hydrogen-Ion Concentration; Immun | 2005 |
Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis.
Topics: Adult; Antimicrobial Cationic Peptides; beta-Defensins; Body Fluids; Cytokines; Female; Gardnerella | 2006 |
Lactobacillus strains isolated from the vaginal microbiota of healthy women inhibit Prevotella bivia and Gardnerella vaginalis in coculture and cell culture.
Topics: Anti-Bacterial Agents; Bacterial Adhesion; Coculture Techniques; Female; Gardnerella vaginalis; HeLa | 2006 |
[Acute, hemorrhagic, overgrowing vaginal inflammation caused by Streptococcus agalacitae--case study].
Topics: Acute Disease; Administration, Intravaginal; Anti-Bacterial Agents; Chitosan; Female; Humans; Inflam | 2006 |
Vaginitis.
Topics: Female; Gentian Violet; Humans; Lactic Acid; Lactobacillus; Phenazines; Staining and Labeling; Vagin | 1998 |
[Application of 2% clindamycin cream in the treatment of bacterial vaginosis and valuation of methylcellulose gel containing the complex of Chitosan F and PVP k-90 with lactic acid as carrier for intravaginally adhbited medicines in the cases of pregnanci
Topics: Administration, Intravaginal; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Chitin; Chitosan; | 2001 |